Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adjuvant, aggressive, amenable, Antonio, ASGCT, AST, barrier, baseline, bearing, biochemical, Bioethical, bioreactor, Biosafety, biosimilar, BPCIA, Bridge, brought, Budget, CBER, chain, chart, concentration, concomitant, Conversely, cycle, cytokine, deletion, depigmentation, desirable, desired, Discouraging, disgorgement, dismal, disproportionate, distraction, documentary, downgrade, economy, electrical, elicited, embedded, employed, export, extreme, factual, feasible, flattening, fluctuate, fluctuated, focused, Fondazione, forty, freedom, frequent, frequently, Germanton, glioblastoma, glioma, Glybera, illegally, immunostimulatory, immunotherapeutic, immunotherapy, impede, Impeding, imposition, inadvertent, inappropriate, inclusion, incompetent, Inflammation, inside, intact, interchangeable, intricate, inventorship, IRB, irrevocable, Istituto, Italy, Joint, jurisdiction, Kevin, Lafond, lengthen, lesion, lifetime, mental, mesenchymal, mice, microenvironment, misappropriated, modest, monoclonal, monotherapy, mRNA, multicenter, multigenic, murine, Navy, Nazionale, NIH, nonclinical, occupied, occupying, official, onForm, optimal, output, overcome, pathway, penetration, perception, pharmacovigilance, physical, pipeline, Plaza, poster, potent, Presidential, Principlesto, properly, RAC, rapidly, Recall, recombinant, recordkeeping, refine, regulatable, release, Relief, reproduce, resection, resell, respond, restitution, revise, revision, SABC, San, seizure, senior, serum, session, shortly, shrinkage, Sidra, signaling, silence, skeletal, SOC, social, solved, standby, stem, stringent, subtenant, surgical, Symposium, Taxpayer, team, telecommunication, temozolomide, terrorism, trail, trillion, Tumori, underwent, undue, unexpected, UniQure, unknown, unwilling, valuable, variable, veledimex, viability, visibility, visible, vulnerable, war, wholly, workforce, Yard
Removed:
accumulation, acute, addressing, age, ago, alkaloid, alkylating, antitumor, array, arrhythmia, assigned, ATO, atorsade, atrioventricular, bendamustine, binding, black, bladder, block, box, broad, cardiac, cartilage, central, cervical, CHOP, chromosome, clearance, colchicine, colon, compendia, connective, considerably, consistently, CT, curable, de, deliver, destabilization, detectable, docetaxel, dysgeusia, encouraging, excellent, expedited, fat, fatal, forin, fuzzy, head, heart, histological, histology, homogeneity, HuT, improved, inconvenient, induced, inhibition, inhibitory, inorganic, interfere, interval, intratumorally, inversely, inviting, IPM, irritation, kidney, ligand, light, mainstay, marrow, mesna, microtubule, microtubulesin, moderate, moderately, multidrug, myelodysplastic, neck, neuropathy, NHL, notably, older, onin, opening, opposite, orally, ovarian, ovary, paclitaxel, pancreatic, pharmacology, placebo, poorer, postpone, prolongation, promyelocytic, prostate, protective, QT, reaching, regression, reincorporation, relapsed, relied, renal, repeated, resistant, revealed, rodent, spectrum, spite, sponsorship, synergy, TarcevaTM, taste, taxane, Taxol, Taxotere, testicular, throat, tolerated, transplantation, trioxide, Trisenox, UltraVector, unprecedented, uroprotectant, utilizing, ventricular, vinca, vincristine, vinorelbine, vivoeffector, wide, XelodaTM, xenograft
Filing tables
Filing exhibits
Related press release
TCRT similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Forms S-8 (File Nos. 333-129884, 333-134280, 333-142701, 333-160496 and 333-167925) and Forms S-3 (File Nos. 333-129680, 333-134279, 333-141014, 333-161453, 333-162160, 333-163517, 333-166444 and 333-174292) of ZIOPHARM Oncology, Inc. of our report dated February 20, 2014 relating to our audit of the financial statements and the effectiveness of internal control over financial reporting, which appears in this Annual Report on Form 10-K of ZIOPHARM Oncology, Inc. for the year ended December 31, 2013.
/s/McGladrey LLP
Boston, Massachusetts
March 3, 2014